apart
direct
detect
infect
organ
biomark
pathogen
surrog
host
marker
also
use
sensit
earli
diagnosi
pathogen
infect
earli
detect
pathogen
infect
discrimin
among
close
relat
diseas
overlap
clinic
manifest
monitor
diseas
progress
achiev
analyz
blood
biomark
therefor
last
decad
larg
number
proteom
studi
conduct
identifi
differenti
express
human
serumplasma
protein
differ
infecti
diseas
intent
discov
novel
potenti
diagnosticprognost
biomark
howev
indepth
review
literatur
indic
mani
report
biomark
alter
way
multipl
infecti
diseas
regardless
type
infect
might
consequ
gener
acut
phase
reaction
uniqu
modul
candid
differ
pathogen
infect
could
indic
specif
respons
review
articl
provid
comprehens
analysi
differenti
express
serumplasma
protein
variou
infecti
diseas
categor
protein
marker
associ
gener
specif
respons
challeng
associ
discoveri
valid
translat
phase
serumplasma
biomark
establish
also
discuss
spectacular
advanc
proteom
research
achiev
preced
decad
propel
expans
divers
field
clinic
research
field
person
medicin
target
therapeut
gain
popular
integr
person
omic
proeven
though
detect
presenc
caus
organ
pathogenrel
marker
examin
clinic
symptom
gener
use
routin
diagnosi
infecti
diseas
sensit
earli
diagnosi
pathogen
infect
also
achiev
analysi
surrog
host
marker
addit
investig
pathogeninduc
alter
host
proteom
diseas
condit
provid
valuabl
inform
regard
diseas
pathogenesi
host
immun
respons
order
sustain
viabil
within
host
system
ensur
replic
pathogen
develop
versatil
mechan
exploit
host
cell
induc
new
permeabl
pathway
allow
uptak
nutrient
remov
wast
product
significantli
affect
variou
vital
physiolog
process
consequ
modul
host
proteom
upon
infect
continu
interact
pathogen
host
immun
system
initi
complex
immun
respons
hold
back
pathogen
infect
growth
multipl
antiparasit
effector
function
includ
inhibit
invas
cytoadher
antibodydepend
cytotox
cellular
inhibit
serumplasma
protein
use
earli
diagnosi
differenti
infect
similar
etiolog
clinic
manifest
well
monitor
diseas
progress
sinc
mani
compon
blood
proteom
often
exhibit
alter
express
level
consequ
extern
pathogen
infect
show
excel
correl
diseas
progressionsever
larg
number
serumplasma
proteom
studi
aim
identif
novel
potenti
diagnosticprognost
biomark
understand
diseas
pathobiolog
report
past
decad
howev
alter
express
level
potenti
biomark
often
found
nonspecif
alter
multipl
infecti
diseas
irrespect
type
infect
might
effect
inflammationmedi
acut
phase
respons
signal
research
group
investig
alter
human
serum
proteom
differ
infecti
diseas
includ
falciparum
vivax
malaria
dengu
fever
leptospirosi
identifi
common
uniqu
protein
signatur
moreov
compil
list
differenti
express
serum
protein
ten
differ
type
protozoan
viral
bacteri
infecti
diseas
often
fatal
includ
malaria
dengu
mening
acquir
immunodefici
syndrom
aid
sever
acut
respiratori
syndrom
sar
diarrhea
hepat
b
c
tuberculosi
pneumonia
leptospirosi
publish
studi
conduct
use
proteom
immunoassaybas
approach
review
articl
intend
provid
inclus
represent
overlap
specif
protein
alter
human
serumplasma
proteom
due
variou
infecti
diseas
challeng
critic
issu
associ
differ
phase
serumplasma
biomark
discoveri
ventur
also
discuss
analysi
alter
human
serumplasma
proteom
consequ
pathogen
infect
certainli
inform
research
studi
diseas
pathogenesi
host
immun
respons
interest
identifi
diagnost
prognost
host
marker
biomark
indic
biomolecul
assist
earli
diagnosi
discrimin
differ
diseas
provid
valuabl
tool
monitor
progressionsever
diseas
earli
detect
infecti
diseas
could
reduc
complic
secondari
infect
fatal
due
diseas
sever
also
unnecessari
cost
improp
delay
diagnosi
treatment
although
exist
diagnost
approach
includ
analysi
clinic
symptom
microscop
detect
caus
pathogen
organ
molecular
immunolog
diagnost
method
rapid
diagnost
test
usual
implement
clinic
adequ
robust
sensit
detect
pathogen
symptomat
patient
sensit
lower
asymptomat
subject
patient
earli
stage
infect
tabl
furthermor
exist
routin
detect
techniqu
unabl
provid
prognost
inform
regard
infect
clearli
discrimin
among
infect
overlap
clinic
manifest
end
protein
marker
potenti
candid
develop
altern
moresensit
diagnost
prognost
approach
infecti
diseas
identif
panel
biomark
might
attract
detect
specif
infect
well
discrimin
among
nearli
similar
ident
manifest
use
serum
plasma
biolog
fluid
studi
diseas
pathobiolog
identif
biomark
pro
con
plasma
easili
separ
cellular
compon
blood
slightli
higher
volum
plasma
gener
obtain
equal
quantiti
whole
blood
compar
serum
furthermor
plasma
sampl
obtain
quickli
sinc
coagul
time
requir
coagulationinduc
interferencesvari
avoid
contrast
due
absenc
fibrinogen
blood
clot
factor
serum
total
protein
content
complex
reduc
compar
plasma
accord
recent
studi
zimmerman
et
al
involv
pair
comparison
plasma
serum
sampl
individu
neglig
differ
number
peptid
protein
identif
overal
percentag
semitrypt
peptid
methionin
oxid
peptid
two
biolog
fluid
although
higher
variabl
semitrypt
peptid
observ
serum
particular
variat
serum
sampl
introduc
due
inconsist
coagul
separ
process
compar
analysi
human
serum
edta
heparin
citrateanticoagul
plasma
difficult
distinguish
common
respiratori
infect
due
late
seroconvers
wk
serolog
diagnosi
suitabl
earli
detect
viru
isol
process
riski
facil
requir
extens
expens
pcrbase
molecular
diagnosi
expens
afford
develop
countri
tuberculin
skin
test
tst
radiolog
chest
xray
cultur
speci
identif
immunolog
test
pcrbase
molecular
diagnost
interferonreleas
assay
igra
qftit
assay
crossreact
low
specif
tst
falseneg
result
immunocompromis
patient
youngold
person
cultur
process
prolong
sinc
caus
organ
slowgrow
qftit
poor
specif
chest
xray
alon
conclus
pneumonia
bacteri
streptococcu
haemophilu
chlamydophila
viral
chest
xraysct
scan
creactiv
protein
procalcitonin
measur
blood
blood
cultur
speci
identif
pcrbase
molecular
diagnost
invas
test
chest
xraysct
scan
specifi
infect
pathogen
determin
pneumonia
etiolog
sensit
blood
cultur
method
low
unabl
detect
etiolog
pcrbase
diagnosi
expens
identifi
nonpneumophila
legionella
pneumonia
speci
diagnosi
commun
acquir
pneumonia
cap
challeng
due
similar
common
cold
flu
leptospirosi
bacteri
spirochet
genu
leptospira
microscop
examin
difficult
detect
low
level
pathogen
train
personnel
requir
difficult
detect
earli
stage
infect
culturebas
detect
tediou
time
consum
complic
expens
mat
complex
experienc
personnel
requir
pcrbase
detect
expens
ct
comput
tomographi
mri
magnet
reson
imag
csf
cerebrospin
fluid
infect
caus
multipl
differ
microorgan
major
causal
pathogen
list
b
clinic
manifest
sign
symptom
diseas
discuss
also
studi
diagnosi
conduct
human
proteom
organis
hupo
clearli
indic
plasma
edta
citrat
anticoagul
provid
reproduc
result
serum
therefor
plasma
recommend
attract
biolog
fluid
proteom
research
differ
step
involv
standard
workflow
proteomicsbas
serumplasma
biomark
discoveri
shown
fig
sampl
collect
protein
extract
process
involv
multipl
step
often
includ
deplet
highabund
protein
prefraction
prior
standard
work
flow
differ
proteom
approach
commonli
use
serumplasma
biomark
discoveri
prior
proteom
analysi
deplet
highabund
protein
prefraction
overal
proteom
perform
reduc
complex
dynam
rang
protein
concentr
serumplasma
sampl
order
perform
compar
proteom
profil
control
diseas
sampl
varieti
gelbas
msbase
arraybas
techniqu
use
result
obtain
initi
discoveri
phase
usual
valid
immunoassaybas
approach
elisa
western
blot
subsequ
roc
curv
multivari
statist
analysi
perform
determin
specif
sensit
class
predict
accuraci
identifi
potenti
marker
protein
actual
proteom
analysi
due
complex
serumplasma
sampl
wide
dynam
rang
protein
concentr
lead
unintend
remov
protein
bound
protein
target
remov
differ
gel
ms
arraybas
techniqu
appli
compar
proteom
profil
result
obtain
discoveri
phase
usual
valid
use
immunoassaybas
approach
reader
direct
protocol
specif
articl
refer
fig
technolog
detail
work
principl
differ
proteom
approach
shown
final
specif
sensit
predict
accuraci
identifi
potenti
marker
protein
evalu
receiv
oper
characterist
roc
curv
multivari
statist
analys
perform
comprehens
analysi
publish
literatur
order
evalu
overlap
uniqu
signatur
serumplasma
marker
ten
oftenfat
protozoan
viral
bacteri
infecti
diseas
includ
malaria
dengu
mening
aid
sar
diarrhea
hepat
b
c
tuberculosi
pneumonia
leptospirosi
experiment
detail
eg
sampl
type
popul
size
type
control
technolog
employ
discoveri
valid
phase
studi
import
identifi
differenti
express
protein
mani
select
proteom
immunoassaybas
studi
infecti
diseas
provid
tabl
critic
analysi
publish
literatur
variou
research
group
clearli
indic
express
level
mani
report
potenti
biomark
modul
similarli
sever
infecti
diseas
irrespect
type
pathogen
might
result
gener
acutephasestress
reaction
specif
modul
candid
differ
pathogen
infect
could
indic
uniqu
respons
differenti
express
profil
select
serum
protein
differ
infecti
diseas
shown
fig
serumplasma
protein
show
opposit
trend
differenti
express
infect
compar
type
infecti
diseas
promis
candid
diagnosi
discrimin
analysi
interestingli
serum
level
haptoglobin
hp
found
significantli
lower
malaria
patient
plasmodium
vivax
plasmodium
falciparum
infect
hp
posit
acut
phase
protein
exhibit
upregul
infecti
diseas
fig
support
inform
tabl
hp
sequest
free
hemoglobin
hb
releas
pathogeninduc
hemolysi
hphb
complex
lead
hypoor
ahaptoglobinemia
hp
promis
inflammatori
marker
evalu
sever
plasmodium
infect
potenti
epidemiolog
marker
malaria
addit
compar
analysi
variou
infecti
diseas
indic
even
though
protein
saa
crp
exhibit
similar
trend
differenti
express
upregul
multipl
infect
level
regul
fold
chang
found
quit
differ
depend
type
infecti
agent
candid
could
effect
classifi
discrimin
among
differ
infecti
manifest
fig
shown
establish
panel
serum
biomark
rather
singl
candid
much
effect
detect
specif
infect
discrimin
clinic
relat
febril
ill
proteom
analys
found
panel
identifi
protein
consist
six
candid
serum
amyloid
hemopexin
apolipoprotein
e
haptoglobin
retinolbind
protein
apolipoprotein
ai
discrimin
among
malaria
dengu
leptospirosi
although
six
protein
uniqu
malaria
dengu
leptospirosi
combin
specif
trend
level
differenti
express
allow
success
discrimin
among
three
infecti
diseas
overlap
clinic
manifest
within
panel
individu
class
predict
potenti
candid
marker
evalu
becom
appar
play
specif
contribut
discrimin
particular
infect
healthi
popul
relat
clinic
manifest
therefor
feel
combin
clinicopatholog
paramet
serumplasma
marker
provid
improv
predict
accuraci
diseas
mani
serumplasma
protein
serotransferrin
serum
albumin
etc
exhibit
similar
trend
differenti
express
multipl
infect
basic
nonspecif
indic
inflamm
stress
respons
promis
diagnosticprognost
point
view
fig
often
isol
proteom
studi
diseas
versu
healthi
control
compar
differenti
express
candid
found
mani
simpli
consequ
gener
acut
phase
reaction
misclaim
promis
marker
fig
reallif
scenario
biomark
candid
commonli
alter
multipl
infecti
diseas
effect
discrimin
differ
clinic
manifest
unless
level
differenti
express
candid
protein
significantli
differ
infect
use
part
marker
panel
along
specif
candid
review
demonstr
frequent
appear
atp
synthas
enolas
differenti
express
candid
variou
publish
tissu
proteom
analys
perform
use
combin
ms
univers
candid
probabl
exclud
list
promis
target
may
actual
biomark
specif
diseas
state
even
though
serumplasma
proteom
analysi
gain
consider
attent
investig
pathogeninduc
alter
human
host
identif
potenti
diagnost
prognost
marker
variou
infecti
diseas
quit
basic
challeng
associ
discoveri
valid
translat
phase
serumplasma
biomark
mostli
due
variat
sampl
collect
process
step
fig
ptm
presenc
multipl
isoform
protein
sampl
complex
preanalyt
variat
introduc
sampl
collect
handl
storag
process
also
challeng
determin
true
biomark
addit
complex
biolog
sampl
wide
dynam
rang
protein
concentr
plasma
presenc
highabund
protein
mask
lowabund
marker
protein
high
level
salt
interf
compound
insuffici
sensit
detect
technolog
low
throughput
major
obstacl
discoveri
blood
biomark
despit
recent
technolog
advanc
sever
limit
current
proteom
technolog
frequent
use
discoveri
diseaserel
marker
protein
serumplasma
sampl
detail
technolog
limit
associ
differ
type
proteom
approach
discuss
elsewher
gelbas
msbase
arraybas
labelfre
proteom
often
experienc
proteom
biomark
discoveri
studi
excit
promis
find
base
smaller
popul
size
fail
live
expect
valid
stage
subsequ
larger
clinic
trial
part
biolog
variabl
lack
reproduc
techniqu
use
standard
proteomicbas
blood
biomark
discoveri
workflow
candid
screen
discoveri
phase
often
lead
identif
nearli
differenti
express
candid
fulfil
statisticalfoldchang
criteria
usual
one
tenth
confirm
validationfollowup
phase
target
analysi
perform
bigger
clinic
cohort
use
altern
technolog
approach
gradual
number
decreas
even
clinic
trial
ultim
identifi
marker
found
real
clinic
applic
receiv
food
drug
administr
fda
approv
fig
point
biomark
biomark
panel
actual
verif
valid
stage
techniqu
use
biomark
discoveri
gener
suitabl
valid
purpos
antibodybas
method
immunoassaybas
valid
western
blot
elisa
expens
use
huge
number
potenti
candid
identifi
discoveri
phase
highli
multiplex
end
msbase
target
proteom
approach
particularli
srm
mrm
come
fore
altern
valid
method
order
acquir
result
extrapol
across
studi
popul
consider
critic
factor
begin
design
clinic
proteom
studi
biomark
discoveri
indispens
select
appropri
control
crucial
discoveri
phase
identif
indisput
biomark
human
diseas
fig
frequent
research
compar
specif
diseas
state
healthi
subject
control
whatev
differenti
express
serumplasma
protein
satisfi
statisticalfoldchang
criteria
report
potenti
biomark
regardless
specif
biomark
particular
diseas
consequ
variou
publish
articl
compar
becom
evid
differenti
express
serumplasma
protein
compar
healthi
control
identifi
isol
studi
differ
research
group
report
potenti
biomark
specif
infect
might
fact
marker
multipl
infecti
diseas
therebi
use
reliabl
diagnost
marker
specif
diseas
divers
socioepidemiolog
background
ethnic
lifestyl
diet
exposur
variou
environment
risk
factor
infecti
agent
hormon
relat
variabl
significantli
affect
compon
serumplasma
proteom
consequ
select
control
diseas
popul
compar
sex
ratio
age
rang
demograph
featur
dietari
consider
essenti
minim
preanalyt
variat
clinicopatholog
detail
particularli
inform
regard
past
histori
infect
relaps
case
presenc
mixedasymptomat
infect
crucial
analysi
serumplasma
proteom
infecti
diseas
sinc
lack
detail
inform
may
lead
misinterpret
obtain
result
therefor
meticul
track
variabl
extrem
import
obtain
reproduc
result
downstream
analysisinterpret
find
end
develop
countri
stabl
biobanksbiorepositori
organ
collect
storag
huge
number
biospecimen
comprehens
clinicopatholog
socioepidemiolog
inform
acceler
largescal
clinic
studi
countri
low
resourc
set
due
pauciti
stabl
biobank
activ
obtain
wellannot
biospecimen
often
challeng
understand
possibl
sourc
preanalyt
variabl
subsequ
impact
quantif
peptid
protein
concentr
serumplasma
sampl
extrem
crucial
sinc
advers
influenc
ultim
find
reproduc
entir
analysi
process
gelfand
omenn
provid
comprehens
systemat
analysi
divers
sourc
preanalyt
variabl
plasma
serum
proteom
analysi
recommend
experiment
guidelin
reduc
undesir
variat
introduc
multipl
sourc
sampl
collect
handl
process
step
addit
sociodemograph
clinicopatholog
background
patient
venepunctur
phlebotomi
strategi
sampl
collect
devic
intrins
enzym
activ
durat
environ
sampl
process
ship
storag
condit
major
sourc
preanalyt
variabl
fig
recent
studi
zhao
et
al
shown
influenc
preanalyt
variat
blood
sampl
handl
find
quantit
immunoassay
rheumatoid
arthriti
find
obtain
studi
indic
effect
blood
sampl
collect
process
handl
process
minim
autoantibodi
biomark
measur
variabl
substanti
affect
serum
protein
concentr
yi
et
al
demonstr
timedepend
alter
human
plasma
serum
protein
due
proteolyt
degrad
intrins
plasma
peptidas
proteas
recommend
addit
proteas
inhibitor
instantan
blood
sampl
collect
process
increas
stabil
plasma
protein
prevent
proteolysisrel
preanalyt
variabl
repeat
freezethaw
cycl
also
affect
serumplasma
protein
stabil
reproduc
obtain
result
avoid
taken
whole
use
optim
blood
collect
devic
reduct
time
elaps
blood
collect
subsequ
process
control
sampl
handl
procedur
environ
stabl
storag
temperatur
avoid
multipl
freezethaw
cycl
cumul
reduc
sampl
instabl
preanalyt
variat
associ
serumplasma
proteom
biomark
studi
anoth
vital
issu
determin
popul
size
diseas
control
discoveri
valid
phase
biomark
discoveri
fig
definit
clinic
cohort
studi
better
confid
level
find
nevertheless
analysi
cost
avail
suitabl
clinic
sampl
often
constrain
investig
bigger
clinic
cohort
prior
compar
proteom
analysi
power
calcul
perform
estim
minimum
number
biolog
replic
requir
diseas
control
popul
recent
studi
gandhi
et
al
shown
power
calcul
analysi
dige
experi
requir
least
ten
sampl
group
confid
differ
p
signific
level
howev
minimum
sampl
size
depend
type
analysi
studi
popul
reproduc
experiment
approach
implic
gener
advis
perform
valid
studi
employ
larger
clinic
cohort
sampl
size
use
discoveri
phase
design
appropri
proteom
experi
involv
differ
type
febril
subject
diseas
control
valid
initi
find
larger
clinic
cohort
use
altern
technolog
approach
essenti
obtain
conclus
protein
marker
specif
infect
subsequ
translat
real
clinic
applic
anoth
controversi
issu
clinic
proteom
profil
experi
analysi
pool
sampl
certainli
inform
obtain
analysi
individu
sampl
much
reliabl
analysi
pool
sampl
sinc
pool
sampl
may
effect
reflect
real
biolog
alter
moreov
actual
differ
might
mask
due
presenc
outlier
extrem
biolog
variabl
within
pool
cohort
nevertheless
pool
clinic
sampl
often
practic
quantit
proteom
analysi
particularli
larger
number
sampl
need
studi
adequ
amount
sampl
individu
analysi
proteom
investig
use
pool
sampl
accept
multipl
small
pool
control
diseas
sampl
analyz
rather
prepar
singl
pool
set
contain
sampl
analyz
sampl
pool
perform
discoveri
phase
analysi
essenti
valid
result
individu
diseas
control
sampl
select
randomli
pool
popul
major
publish
studi
alter
serumplasma
proteom
pathogen
infect
exhibit
map
differenti
express
proteom
singl
time
point
diseas
progress
gener
febril
phase
infect
singl
timepoint
analysi
case
vs
control
involv
earli
febril
stage
infect
may
help
identifi
potenti
diagnost
marker
longitudin
studi
infecti
diseas
involv
repeat
observ
subject
long
period
time
earli
febril
defervesc
convalesc
stage
infect
provid
addit
valuabl
inform
regard
chang
identifi
diseas
marker
util
diseas
monitor
prognost
marker
fig
end
serum
proteom
cytokin
analysi
longitudin
cohort
dengu
fever
lifethreaten
complic
dengu
hemorrhag
fever
recent
report
kumar
et
al
author
shown
indepth
investig
serum
proteom
signatur
differ
timepoint
infect
correl
analysi
clinicopatholog
paramet
help
unravel
mechan
dengu
diseas
progress
howev
collect
sampl
multipl
time
point
patient
sever
infect
often
problemat
due
ethic
concern
due
variou
technolog
limit
complex
wide
dynam
rang
protein
concentr
plasmaserum
sampl
comprehens
coverag
entir
blood
proteom
extrem
challeng
often
lowabund
potenti
biomark
miss
individu
studi
conduct
use
singl
proteom
profil
approach
goal
map
maximum
number
protein
present
human
plasma
hupo
introduc
human
ppp
advanc
biomark
discoveri
valid
process
multipl
intern
collabor
includ
total
laboratori
across
globe
object
hupo
ppp
includ
comprehens
analysi
entir
protein
compon
human
plasma
serum
identif
dynam
biolog
physiolog
variat
plasma
proteom
within
individu
well
estim
extent
variat
individu
within
differ
popul
normal
diseas
condit
would
extrem
use
design
clinic
studi
pilot
phase
hupo
ppp
includ
result
collabor
laboratori
analyt
group
gener
core
dataset
protein
two
highconfid
peptid
reduc
protein
stringent
select
criteria
implement
separ
analysi
dataset
addit
hupo
ppp
human
plasma
peptid
atla
establish
incorpor
lcmsm
shotgun
proteom
result
sever
experi
conduct
variou
laboratori
anoth
resourc
studi
human
plasma
protein
continu
hupo
ppp
initi
subsequ
phase
hupo
ppp
commenc
hupo
world
congress
proteom
amsterdam
netherland
encourag
submiss
highqual
larg
dataset
human
plasma
proteom
analysi
develop
comprehens
data
repositori
integr
ppp
diseaserel
initi
hupo
regard
plasmaserum
biomark
discoveri
recent
year
omicsbas
research
work
toward
indepth
analysi
ptm
splice
variant
obtain
inform
beyond
differenti
express
analysi
candid
proteinsgen
often
found
inadequ
understand
complex
biolog
process
diseas
pathobiolog
recent
hupo
initi
chromosomecentr
project
hpp
provid
systemat
catalog
protein
relat
chromosom
contrast
provid
diseaseori
approach
bdhpp
share
scientif
data
among
differ
research
group
across
world
crucial
improv
proteomicsbas
biomark
discoveri
endeavor
sinc
allow
differ
research
commun
access
evalu
valid
find
correl
result
observ
comparison
extrapol
data
gener
differ
research
laboratori
possibl
uniform
standard
proteom
procedur
neglig
preanalyt
technolog
variat
practic
global
end
hupo
psi
http
psidevsourceforgenet
establish
develop
univers
refer
standard
use
proteom
studi
standard
method
follow
introduc
uniform
reproduc
data
acquisit
analysi
process
turn
acceler
comparison
exchang
interpret
data
avoid
fragment
proteom
data
gener
differ
research
laboratori
across
globe
hupo
psi
committe
work
develop
standard
oper
procedur
qualiti
assur
protocol
data
handl
analysi
global
scale
moreov
hupo
psi
goal
develop
report
requir
data
exchang
format
control
vocabulari
formal
requir
proteom
commun
encourag
particip
multidisciplinari
collabor
project
function
genom
experi
fuge
function
genom
investig
ontolog
fugo
order
acceler
collat
comparison
analysi
multiom
dataset
hupo
psi
specifi
standard
alreadi
success
implement
field
ms
molecular
interact
includ
traml
format
exchang
srm
transit
list
mzidentml
data
standard
msbase
proteom
result
psicquic
psiscor
access
score
molecular
interact
intern
molecular
exchang
imex
consortium
protein
interact
data
curat
accord
assess
within
year
establish
hupo
psi
gain
consider
popular
among
proteom
commun
worldwid
establish
foremost
repres
field
proteom
facilit
data
comparison
exchang
verif
continu
introduct
new
proteom
technolog
improv
sensit
highthroughput
capabl
overcom
exist
technolog
limit
integr
proteom
research
emerg
research
field
collabor
research
work
global
scale
also
essenti
translat
exist
knowledg
practic
clinic
applic
develop
simpl
accur
low
cost
stabl
diagnost
test
implement
test
develop
countri
crucial
sinc
approxim
infecti
diseaseassoci
death
occur
develop
countri
mainli
due
lack
earli
diagnosi
time
treatment
certainli
one
promis
applic
proteom
clinic
identif
next
gener
diagnost
prognost
diseas
biomark
effect
improv
diagnost
therapeut
highthroughput
proteom
technolog
suitabl
rapid
screen
quantif
thousand
analyt
high
accuraci
need
find
authent
biomark
ultim
primari
object
proteom
biomark
discoveri
research
establish
novel
candid
marker
clinic
use
well
translat
exist
find
practic
applic
diagnost
therapeut
howev
spite
tremend
potenti
actual
bedsid
translat
find
obtain
proteom
research
thu
far
limit
effort
proteom
commun
start
show
result
evid
success
stori
test
obtain
fda
clearanc
even
though
biomark
identifi
variou
proteom
studi
show
promis
discoveri
phase
get
approv
without
pass
valid
stage
clinic
trial
complex
longterm
procedur
global
initi
human
ppp
human
plasma
peptid
atla
hupo
psi
design
identifi
character
inclus
proteom
plasma
connect
exist
plasmaserum
proteom
studi
across
world
establish
highqual
uniform
standard
proteom
analysi
also
collect
respons
individu
research
group
integr
research
find
ongo
worldwid
initi
